Article
EGFR-mutated stage IV non-small cell lung cancer: What is the role of radiotherapy combined with TKI?
Cancer medicine - 1 Sept 2021
Liu Bailong, Liu Hui, Ma Yunfei, Ding Qiuhui, Zhang Min, Liu Xinliang, Liu Min
Abstract excerpt
Lung cancer is the leading cause of cancer-related death globally and poses a considerable threat to public health. Asia has the highest prevalence of epidermal growth factor receptor (EGFR) mutations in patients with non-small cell lung cancer (NSCLC). Despite the reasonable response and prolonged survival associated with EGFR-tyrosine kinase inhibitor (TKI) therapy, the acquisition of resistance to TKIs remains...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
